March 3, 2025
Envol Biomedical, in collaboration with ClearPoint Neuro, is excited to announce an upcoming webinar that will delve into the latest advancements in CNS (central nervous system) drug delivery. Scheduled for April 16th, this exclusive session will explore innovative techniques in MRI-guided neurosurgical approaches for assessing gene transport in the brain. If you’re involved in pharmaceutical research, biotech development, or preclinical studies targeting the CNS, this is a must-attend event.
Why Attend?
The field of CNS drug development is rapidly evolving, with increasing interest in precise and effective dosing strategies. This webinar will provide an in-depth look at best practices for direct drug administration to the brain and spinal column, leveraging cutting-edge image-guided technologies.
Our expert speakers will discuss:
– Techniques for direct injection into specific brain regions and intrathecal spaces.
– Measurement of biodistribution and biological endpoints in CNS studies.
– Lessons learned from past studies, including both successful approaches and potential pitfalls.
– Novel techniques in visualizing gene transport using fluorescent tagging and tomography imaging.
– The role of MRI guidance in ensuring accurate drug delivery and minimizing off-target effects.
– Insights into designing effective CNS-targeting programs, considering technical challenges and best practices.
Featured Experts
This webinar will be co-hosted by leading experts from Envol Biomedical and ClearPoint Neuro, including:
– Jake McDonald, CEO of Envol Biomedical
– Rainier Espinoza, Lead Surgeon and Study Director, Envol Biomedical
– Expert Investigator from ClearPoint Neuro, specializing in FDA-approved technology for MRI-guided brain infusions
What to Expect
Attendees will gain insights into the latest research methodologies used to optimize CNS-targeted drug delivery. A key highlight of the session will be the presentation of novel data from a pilot study conducted by Envol and ClearPoint Neuro. This study utilized AAV-based gene therapy with fluorescent tagging, allowing for advanced visualization of biodistribution through histological and tomography-based imaging techniques.
During the webinar, the speakers will discuss a groundbreaking approach where a fluorescent-tagged transgene was delivered via AAV to the brain, enabling visualization using histological techniques and tomography imaging. This innovative approach allowed researchers to generate highly detailed 3D reconstructions of biodistribution patterns, layered with MRI anatomical data to create a comprehensive visualization of gene transport. This type of data is invaluable for researchers designing CNS-targeted drug delivery programs, as it provides both qualitative and quantitative insights into treatment efficacy and precision.
The webinar will also address translational considerations for CNS drug delivery, highlighting the experiences and expertise of Rainier Espinoza, a clinical neurosurgeon who has adapted his surgical skills for nonclinical research applications. His insights will be particularly valuable for professionals looking to bridge the gap between preclinical research and clinical implementation.
Who Should Attend?
This session is designed for:
– Preclinical pharmaceutical scientists
– Drug development professionals in the biotech and pharmaceutical industries
– Researchers focusing on pharmacology, pharmacokinetics, biodistribution, or toxicology of CNS-targeted therapies
– Neuroscientists and clinicians interested in cutting-edge CNS drug delivery methodologies
By attending, you’ll gain a clearer understanding of how to design more effective CNS drug delivery studies and avoid common pitfalls in the field.
Register Now
Don’t miss this opportunity to learn from industry leaders and gain exclusive insights into cutting-edge CNS drug delivery strategies. The webinar is free to attend but requires prior registration.
📅 Date: April 16th, 2024
⏰ Time: 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
📍 Virtual Event
